Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

Soussain, Carole; Hoang-Xuân, Khê; Taillandier, Luc; Fourme, Emmanuelle; Choquet, Sylvain; Witz, Francis; Casasnovas, Olivier; Dupriez, Brigitte; Souleau, B.; Taksin, Anne‐Laure; Gisselbrecht, Christian; Jaccard, Arnaud; Omuro, Antonio; Sanson, Marc; Janvier, Maud; Kolb, Brigitte; Zini, Jean Marc; Leblond, Véronique

doi:10.1200/jco.2007.13.5533

Cited by 297 publications

(191 citation statements)

References 24 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…Apart from specific safety concerns consisting of the pulmonary toxicity of carmustine, 8 the Abbreviations: BEAM = carmustine, etoposide, ara-C, melphalan; CR1 = first CR; CR41 = CR in relapse; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; HL = Hodgkin's lymphoma; PR1 = first PR; PR41 = PR in relapse; TEAM = thiotepa, etoposide, ara-C, melphalan; SCT = stem cell transplantation. TT-based HDT is established for auto-SCT in PCNSL, [5][6][7] as well as for systemic non-Hodgkin lymphoma involving the CNS. 9 Acceptable safety profiles and decent efficacy of TT-based HDT regimens provide a rationale for investigating these as alternatives to BEAM also in patients with lymphoma other than PCNSL.…”

Section: Discussionmentioning

confidence: 99%

“…Because of its excellent capacity to cross the blood-brain barrier, it is regularly used as part of HDT followed by auto-SCT for primary central nervous system lymphoma (PCNSL). [5][6][7] Although TT-based myeloablation might compare well with other conventionally used high-dose regimens such as BEAM, clinical-level information about TT-based auto-SCT outside the PCNSL field is sparse. The purpose of the present retrospective study based on the European Society for Blood and Marrow Transplantation (EBMT) database was to provide information on the potential risks and benefits of TT-based high-dose regimens for auto-SCT in distinct subtypes of lymphoma outside the PCNSL setting.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

Sellner

Boumendil

Finel

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

on behalf of the EBMT Lymphoma Working PartyClinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa-and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

Sellner

Boumendil

Finel

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The frequency of IOL in this study of 6.5% is within the range of 1-19% reported in prospective PCNSL patients` series [11][12][13][14][15] . The high range of IOL frequency reported is most probably due to a high proportion of asymptomatic patients and challenges in diagnosing this condition even for trained ophthalmologists.…”

Section: Discussionmentioning

confidence: 53%

Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial

et al. 2014

View full text Add to dashboard Cite

The impact of intraocular involvement (IOL) in primary CNS lymphoma (PCNSL) has not been sufficiently evaluated. Here, we present the analysis of IOL in the only completed randomized phase III trial in PCNSL. The G-PCNSL-SG1 study evaluated the role of whole-brain radiotherapy in primary therapy of PCNSL. Data of the 526 eligible study patients were checked, and clinical characteristics, therapy, and outcome of patients with IOL diagnosed at study inclusion were analyzed. Ophthalmologic examination at study inclusion was performed in 297 patients (56.5 %) of whom IOL was diagnosed in 19 (6.4 %). Clinical characteristics did not significantly differ between patients with IOL (IOL+) and those without (IOL-). The median progression-free survival (PFS) in the IOL+ group was 3.5 months (95 % CI 0.0-7.07) as compared to 8.3 months (95 % CI 4.78-11.78) in the IOL-group (P = 0.004), the median overall survival (OS) was 13.2 months (95 % CI 0.86-25.62) and 20.5 months (95 % CI 15.56-25.5), respectively (P = 0.155). In multivariate analysis, a significantly inferior PFS and OS for IOL+ patients were found. IOL at diagnosis of PCNSL was an independent negative prognostic indicator for PFS and OS in this analysis.

show abstract

“…We thus performed a salvage autologous stem cell transplantation using a blood-brain barrier disrupting conditioning chemotherapy. The TBuCy regimen is a widely approved regimen for CNS lymphoma, allowing long-term disease control even in diseases refractory to chemotherapy [7]. Moreover, this regimen is associated with acute toxicities (particularly neutropenic fever and infection) responsible of a 5-7% toxicity-related mortality, but is not associated with acute or late neurological toxicities [8,9].…”

Section: Discussionmentioning

confidence: 99%

Spinal cord involvement in a Burkitt lymphoma patient

Quentin-Gondard¹,

Legoff²,

Edjlali³

et al. 2017

Cancer Rep Rev

View full text Add to dashboard Cite

show abstract

Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

Abstract: IC + HCR is an effective treatment for refractory and recurrent PCNSL.

Cited by 297 publications

References 24 publications

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial

Spinal cord involvement in a Burkitt lymphoma patient

Contact Info

Product

Resources

About